GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (FRA:NVV1) » Definitions » Cyclically Adjusted Book per Share

Novavax (FRA:NVV1) Cyclically Adjusted Book per Share : €0.00 (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Novavax Cyclically Adjusted Book per Share?

Note: As Cyclically Adjusted Book per Share is a main component used to calculate Cyclically Adjusted PB Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novavax's adjusted book value per share for the three months ended in Mar. 2025 was €-0.394. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Novavax's average Cyclically Adjusted Book Growth Rate was -64.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -41.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -25.60% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -17.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novavax was 8.10% per year. The lowest was -41.40% per year. And the median was -5.10% per year.

As of today (2025-05-13), Novavax's current stock price is €5.788. Novavax's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €0.00. Novavax's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novavax was 35.13. The lowest was 0.39. And the median was 3.21.


Novavax Cyclically Adjusted Book per Share Historical Data

The historical data trend for Novavax's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Cyclically Adjusted Book per Share Chart

Novavax Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.19 7.79 6.28 4.39 1.65

Novavax Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.74 3.01 2.20 1.65 -

Competitive Comparison of Novavax's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Novavax's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Cyclically Adjusted PB Ratio falls into.


;
;

Novavax Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novavax's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.394/134.9266*134.9266
=-0.394

Current CPI (Mar. 2025) = 134.9266.

Novavax Quarterly Data

Book Value per Share CPI Adj_Book
201506 25.711 100.684 34.455
201509 24.239 100.392 32.577
201512 19.903 99.792 26.910
201603 12.299 100.470 16.517
201606 7.236 101.688 9.601
201609 3.271 101.861 4.333
201612 -0.388 101.863 -0.514
201703 -1.925 102.862 -2.525
201706 -3.626 103.349 -4.734
201709 -4.011 104.136 -5.197
201712 -5.319 104.011 -6.900
201803 -4.648 105.290 -5.956
201806 -3.934 106.317 -4.993
201809 -5.673 106.507 -7.187
201812 -7.679 105.998 -9.775
201903 -5.677 107.251 -7.142
201906 -6.994 108.070 -8.732
201909 -6.752 108.329 -8.410
201912 -5.175 108.420 -6.440
202003 -0.403 108.902 -0.499
202006 2.677 108.767 3.321
202009 1.436 109.815 1.764
202012 7.266 109.897 8.921
202103 11.786 111.754 14.230
202106 8.334 114.631 9.810
202109 5.200 115.734 6.062
202112 -4.104 117.630 -4.707
202203 0.759 121.301 0.844
202206 -5.046 125.017 -5.446
202209 -7.284 125.227 -7.848
202212 -6.957 125.222 -7.496
202303 -9.694 127.348 -10.271
202306 -7.385 128.729 -7.741
202309 -5.353 129.860 -5.562
202312 -4.712 129.419 -4.913
202403 -5.683 131.776 -5.819
202406 -2.508 132.554 -2.553
202409 -2.962 133.029 -3.004
202412 -3.714 133.157 -3.763
202503 -0.394 134.927 -0.394

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Novavax  (FRA:NVV1) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novavax was 35.13. The lowest was 0.39. And the median was 3.21.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novavax Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Novavax's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (FRA:NVV1) » Definitions » Cyclically Adjusted Book per Share
Address
700 Quince Orchard Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Novavax Headlines

No Headlines